Jlohr Brain Health
  • Home
  • About Us
  • Brain Health Diagnoses
  • Resources on this Site
    • Overviews: 9 Aspects of this Diagnoses
    • Drug Discount Services
    • With Each Diagnosis:
      • YouTube Video
      • Book from Library or Amazon
      • Support Group or Service
    • Tables for Patients:
      • Possible Special Education
      • Possible Social Security Disability Income
      • School Aid
    • Tables for Patients or Professionals
      • Overview of 9 Aspects of this Diagnosis
      • First Pages of Diagnoses from the Diagnostic and Statistical Manual and the Codes from the ICD-10 for Diagnosis and Compensation
  • Medical & Educational Downloads
  • Contact Us
Select Page

Coenzyme Q10 ameliorates anxiety and depression-like behavior associated with chronic opioid use and increases GDNF expression in the hippocampus of morphine-dependent rats

by jlohrconsulting | Jul 31, 2025 | Uncategorized

Acta Neurobiol Exp (Wars). 2025 Jul 31;85(2):94-104. doi: 10.55782/ane-2025-2581. ABSTRACT Opioid dependence is strongly associated with moderate to severe depression and anxiety. The primary objective of this investigation was to determine whether coenzyme Q10...

How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression? A VAST-D Report

by jlohrconsulting | Jul 31, 2025 | Uncategorized

J Clin Psychopharmacol. 2025 Jul 31. doi: 10.1097/JCP.0000000000002051. Online ahead of print. ABSTRACT BACKGROUND: Many patients view the return of “positive mental health” (PMH) to be their most important goal of treatment for major depressive disorder...

Maternity Leave, Race, and Postpartum Depression: The Impact of Public Policy on Mothers Living in Poverty

by jlohrconsulting | Jul 31, 2025 | Uncategorized

Fam Community Health. 2025 Jul 31. doi: 10.1097/FCH.0000000000000441. Online ahead of print. ABSTRACT BACKGROUND: Some maternity leave practices are associated with postpartum depressive (PPD) symptoms which in turn are linked with increased risk of poor maternal and...

Innovative pharmacological depression treatment

by jlohrconsulting | Jul 31, 2025 | Uncategorized

Eur Arch Psychiatry Clin Neurosci. 2025 Jul 31. doi: 10.1007/s00406-025-02040-w. Online ahead of print. NO ABSTRACT PMID:40742437 | DOI:10.1007/s00406-025-02040-w

Measurement properties of the PROMIS-29 profile v2.1 in a Norwegian rehabilitation context

by jlohrconsulting | Jul 31, 2025 | Uncategorized

J Patient Rep Outcomes. 2025 Jul 31;9(1):98. doi: 10.1186/s41687-025-00929-7. ABSTRACT INTRODUCTION: Psychometric properties of the Patient-Reported Outcomes Measurement Information System® Profile 29 (PROMIS-29) Norwegian version has previously been examined in a...

Pre-radiotherapy multidisciplinary survivorship care and patient-reported outcomes in head and neck cancer survivors

by jlohrconsulting | Jul 31, 2025 | Uncategorized

Support Care Cancer. 2025 Jul 31;33(8):734. doi: 10.1007/s00520-025-09797-9. ABSTRACT PURPOSE: This study aims to evaluate the association between receiving pre-radiotherapy multidisciplinary survivorship care and patient-reported outcomes measures (PROMs) pertaining...
« Older Entries
Next Entries »

Recent Posts

  • Dissociative Drug-Induced Anxiety
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)

Recent Comments